This article covers key health news including Primary Health Properties securing a takeover bid for Assura, Novo Nordisk's ...

A Singapore court has upheld a worldwide freezing order against a local biosciences company in support of a US$830 million ...

Eli Lilly and Company faces valuation pressure after disappointing Orforglipron results. Discover why now isn't the time to ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could ...

If Novo Nordisk A/S’s wildly popular weight-loss drug succeeds in a highly anticipated trial for Alzheimer’s disease, Biogen Inc.’s Chief Executive Officer Chris Viehbacher doesn’t see it as a ...

Novo Nordisk (($DE:NOVA)) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk recently completed a clinical study ...

A new study connects PFA or forever chemical exposure to incident type 2 diabetes risk. Experts explain the findings and how ...

The obesity market still only has two clear leaders with approved GLP-1 medications, and frontrunners Eli Lilly and Novo ...

Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 on track for the second half of 2025 — Completed dosing of over 80% of planned REWRITE healthy volunteers across multiple single asce ...

The partnership means that Apple's fitness and wellness service will be made available to all members who enrol onto ...

Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway ...